Is the psoriasis plaque test still relevant in the age of biologicals?;Ist der psoriasis-plaque-test im zeitalter der biologics noch aktuell?

Hautarzt

Volumn 57, Issue 8, 2006, Pages 672-678

  Wozel, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Antipsoriatic activity; In vivo investigation; Psoriasis; Psoriasis plaque test (PPT); Screening investigations

Indexed keywords

ANTIPSORIASIS AGENT; BETAMETHASONE BENZOATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCINEURIN INHIBITOR; CALCIPOTRIOL; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; DITHRANOL; FLUMETASONE PIVALATE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; GLUCOCORTICOID; PREDNISOLONE; TAZAROTENE;

ARTICLE; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PSORIASIS VULGARIS; SCREENING TEST; SKIN COLOR; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; CALCINEURIN; CALCITRIOL; CHOLECALCIFEROL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; HUMANS; PSORIASIS; RODENTIA; SKIN;

EID: 33748936305     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1182-z     Document Type: Article

References (37)

1. Behrendt H, Korting HC (1990) Klinische Prüfung von erwünschten und unerwünschten topisch applizierbarer Glukokortikosteroide am Menschen. Hautarzt 41: 2-8
2. Berardesca E, Maibach HI (1988) Skin occlusion: treatment or drug-like device? Skin Pharmacol 1: 207-215
3. Bladon PT, Cooper NF, Wood EJ, Cunliffe WJ (1986) Biochemical markers in the mouse tail model of psoriasis. In: Marks R, Plewig G (eds) Skin models; models to study function and disease of skin. Springer, Berlin Heidelberg New York Tokyo, pp 172-182
4. Bollag E (1974) Therapeutic effects of an aromatic retinoic acid analog on chemical induced skin papillomas and carcinomas of mice. Eur J Cancer 10: 731-737
5. Christophers E, Mrowietz U (1995) The inflammatory infiltrate in psoriasis. Clin Dermatol 13: 131-135
6. Dumas KJ, Scholtz JR (1972) The psoriasis bio-assay for topical corticosteroid activity. Acta Dermatol Venereol 52: 43-48
7. Geilen CC, Mrowietz U (2000) Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. J Am Acad Dermatol 42: 837-840
8. Lindberg M, Johannesson A, Forslind B (1982) The effect of occlusive treatment on human skin. An electron microscopic study on epidermal morphology as affected by occlusion and dansyl chloride. Acta Dermatol Venereol 62: 1-5
9. Maibach HI, Lowe NJ (1985) Models in Dermatology 2, dermatopharmacology and toxicology. Karger, Basel München Paris London New York Tokyo Sydney
10. Marks J, Rogers S, Chadrik B, Shuster S (1981) Clearance of chronic plaque psoriasis by anthralin - subjective and objective assessment and comparison with photochemotherapy. Br J Dermatol 105: 96-99
11. Marks R, Barton SP (1989) Assessment of disease progress in psoriasis. Arch Dermatol 125: 235-240
12. Mehlis S, Gordon KB (2004) From laboratory to clinic: rationale for biologic therapy. In: Menter A, Cather J (eds) Dermatologic clinics - psoriasis. Saunders. Philadelphia London Toronto Montreal Sydney Tokyo, pp 371-377
13. McCullough JL, Weinstein GD, Ziboh VA (1985) Cell kinetics in psoriasis. The use of animal and human skin models. In: Maibach HI, Lowe NJ (eds) Models in dermatology. Karger, Basel, pp 51-58
14. Moon RC (1993) Retinoids in experimental oncology. In: Hong WK, Lotan R (eds) Retinoids in oncology. Marcel Dekker, New York Basel Hong Kong, pp 109-125
15. Mrowietz U, Graeber M, Bräutigam M, et al. (1998) The novel ascomycin derivative SDZ AASM 981 is an effective anti-psoriatic compound when used topically under occlusion. Br J Dermatol 139: 992-996
16. Newton JA, Boodle KM, Dowd PM, Greaves MW (1988) Topical NDGA (nordihydroguaiaretic acid) in psoriasis. Br J Dermatol 119: 404-406
17. Nieboer C, Bruynzeel DP, Boorsma DM (1987) The effect of occlusion of the skin with transdermal therapeutic system on Langerhans cells and in the induction of skin irritation. Arch Dermatol 123: 1499-1502
18. Radeke HH, Ludwig RJ, Boehncke WH (2005) Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo. Exp Dermatol 14: 641-666
19. Sano S, Chan KS, Carbajal S et al. (2004) Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11: 43-49
20. Savolainen L, Kontinen J, Alatalo E et al. (1998) Comparison of actual psoriasis surface area and the psoriasis area index by the human eye and machine vision methods in following the treatment of psoriasis. Acta Dermatol Venereol 78: 466-467
21. Schaefer H, Redelmeier TE (1996) Skin barrier - principles of percutaneous absorption. Karger, Basel Freiburg Paris London New York New Delhi Bangkok Singapore Tokyo Sydney
22. Schön MP (1999) Animal models in psoriasis - What can we learn form them? J Invest Dermatol 112: 405-410
23. Schön MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352: 1899-1912
24. Van de Kerkhof, Salonen SH (2003) Large-scale European survey of quality of life in patients with psoriasis: second phase results on quality of life and treatment reported by 7,525 members of European Psoriasis Patient Associations.http://www.psori.fi/doc/patient_survey_2nd_phase(2003).pdf
25. Van Duijnhoven MW, Körver JE, Vissers WH et al. (2006) Effect of calcipotriol on epidermal cell populations in alefacept-treated psoriatic lesions. J Eur Acad Dermatol Venereol 20: 27-33
26. Van Scott EJ (1986) Lesional heterogeneity in psoriasis and therapeutic relevance. In: Farber EM, Nall LM, Morrhenn V, Jacobs PH (eds) Proceedings of the Forth International Symposium. Stanford, pp 6-11
27. Weinstein GD, McCullough JL, Eaglestein WH et al. (1981) A clinical screening program for topical chemotherapeutic drugs in psoriasis. Arch Dermatol 117: 388-393
28. Wendt H, Frosch PJ (1982) Klinisch-pharmakologische Modelle zur Prüfung von Coticoidexterna. Karger, Basel München Paris London New York Tokyo Sydney
29. Winterfield LS, Menter A (2004) Infliximab. Dermatol Ther 17: 409-426
30. Wolff HH, Kreusch JF, Wilhelm KP, Klaus S (1993) The psoriasis plaque test and topical corticosteroids: evaluation by computerized laser profilometry. In: Korting HC, Maibach HI (eds) Topical glucocorticosteroids with increased benefit/risk ratio. Karger, Basel, pp 107-113
31. Wozel G, Barth J (1986) Fluocinolonacetonid und Psoriasis - kontinuierliche oder alternierende Therapie? Dermatol Monatsschr 172: 620-623
32. Wozel G, Barth J (1989) Untersuchungen zur Wirksamkeit von topischer Corticosteroidkombination bei Psoriasis. Z Klien Med 44: 2279-2281
33. Wozel G. Barth J (1986) Vergleichende Untersuchungen über die Wirksamkeit topischer Steroide bei Psoriasis. Dermatol Monatsschr 172: 550-553
34. Wozel G (1994) Effektivität der Kombinationsbehandlung mit Calcipotriol und Fluocinolonacetonid im Psoriasis-Plaque-Test. Akt Dermatol 20: 155-158
35. Wozel G (1993) Einschätzung von Calcipotriol (MC 903) im Psoriasis-Plaque-Test. Dermatol Monatsschr 179: 209-211
36. Wrench R (1985) Assessing drugs for psoriasiform diseases and their antiparakeratotic mechanisms using the mouse tail test. In: Maibach HI, Lowe NJ (eds) Models in dermatology. Karger, Basel, pp 76-91
37. Zenz R, Eferl R, Kenner L et al. (2005) Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437: 369-375